carvedilol has been researched along with Hyperkalemia in 4 studies
Hyperkalemia: Abnormally high potassium concentration in the blood, most often due to defective renal excretion. It is characterized clinically by electrocardiographic abnormalities (elevated T waves and depressed P waves, and eventually by atrial asystole). In severe cases, weakness and flaccid paralysis may occur. (Dorland, 27th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To retrospectively investigate the effect of carvedilol and spironolactone plus furosemide, administered concomitantly with an angiotensin II converting enzyme inhibitor (ACE-I) or an angiotensin II receptor blocker (ARB) to patients with chronic heart failure (CHF)." | 7.73 | Carvedilol accelerate elevation of serum potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate or candesartan cilexetil. ( Hirooka, K; Nakayama, D; Saito, M; Takada, M; Yasumura, Y, 2006) |
| "The treatment with carvedilol caused a significant decrease in blood pressure." | 6.70 | Carvedilol does not modulate moderate exercise-induced hyperkalemia in hemodialysis patients. ( Klimek, D; Kokot, F; Nowicki, M; Szewczyk-Seifert, G, 2002) |
| "To retrospectively investigate the effect of carvedilol and spironolactone plus furosemide, administered concomitantly with an angiotensin II converting enzyme inhibitor (ACE-I) or an angiotensin II receptor blocker (ARB) to patients with chronic heart failure (CHF)." | 3.73 | Carvedilol accelerate elevation of serum potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate or candesartan cilexetil. ( Hirooka, K; Nakayama, D; Saito, M; Takada, M; Yasumura, Y, 2006) |
| "The treatment with carvedilol caused a significant decrease in blood pressure." | 2.70 | Carvedilol does not modulate moderate exercise-induced hyperkalemia in hemodialysis patients. ( Klimek, D; Kokot, F; Nowicki, M; Szewczyk-Seifert, G, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Srivastava, S | 1 |
| Kemnic, T | 1 |
| Hildebrandt, KR | 1 |
| Hahn, L | 1 |
| Hahn, M | 1 |
| Saito, M | 1 |
| Nakayama, D | 1 |
| Takada, M | 1 |
| Hirooka, K | 1 |
| Yasumura, Y | 1 |
| Nowicki, M | 1 |
| Szewczyk-Seifert, G | 1 |
| Klimek, D | 1 |
| Kokot, F | 1 |
1 trial available for carvedilol and Hyperkalemia
| Article | Year |
|---|---|
Carvedilol does not modulate moderate exercise-induced hyperkalemia in hemodialysis patients.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Blood Pressure; Carbazoles; Carved | 2002 |
3 other studies available for carvedilol and Hyperkalemia
| Article | Year |
|---|---|
BRASH syndrome.
Topics: Antihypertensive Agents; Atrioventricular Block; Bradycardia; Bumetanide; Carvedilol; Female; Humans | 2020 |
Carvedilol-induced hyperkalemia in a patient with chronic kidney disease.
Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Carbazoles; Carvedilol; Dose-Response Relati | 2015 |
Carvedilol accelerate elevation of serum potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate or candesartan cilexetil.
Topics: Adult; Aged; Aged, 80 and over; Benzimidazoles; Biphenyl Compounds; Carbazoles; Carvedilol; Drug The | 2006 |